Literature DB >> 10623433

Serum concentrations of sIL-2R, IL-6, TGF-beta1, neopterin, and zinc in chronic hepatitis C patients treated with interferon-alpha.

K Grüngreiff1, D Reinhold, S Ansorge.   

Abstract

T lymphocytes and immunoregulatory cytokines play an important role in the host response to hepatitis C virus (HCV) infection. Zinc is required for a wide spectrum of immune functions, including T-cell activity. To determine the clinical significance of the cytokines sIL-2R, IL-6, TGF-beta1, neopterin, and of zinc in chronic heptatitis C virus (HCV) infection, we investigated their concentrations in the serum of 16 patients with chronic HCV infection before, during and at the end of therapy with interferon (IFN) alpha (Roferon A), and after 6 months follow-up. Elevated concentrations of sIL-2R, IL-6, TGF-beta1, and neopterin were found in the serum of all patients prior to therapy, as compared to healthy controls. sIL-2R patterns differed in responders and non-responders. While the mean concentration of sIL-2R (335.75 pg/ml) before therapy was about 40% higher in complete responders (n=4) than in controls (272.20 pg/ml), the mean concentration in non-responders (n=6) was 4-fold higher than in controls (1153.33 pg/ml). During therapy, sIL-2R levels in responders decreased by about 40%. Mean IL-6 concentrations in both complete and partial responders (n=6) decreased continuously during treatment, while mean concentrations in non-responders decreased for only a short time, and increased again after cessation of therapy. Mean levels of TGF-beta1 behaved similarly to those of IL-6. Only negligible differences in mean neopterin levels were found between responders and non-responders over the entire observation time. The mean serum zinc concentrations slightly decreased in all 3 patient groups, the greatest reduction occurring in 3 of the 4 responders. The present findings underscore the importance of the immune system in the pathogenesis of chronic HCV infection. Serum sIL-2R levels may be used as a serological marker of outcome following IFN-alpha treatment. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10623433     DOI: 10.1006/cyto.1999.0504

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  17 in total

1.  Effects of HCV treatment on cytokine expression during HCV/HIV coinfection.

Authors:  Jason T Blackard; Minhee Kang; Kenneth E Sherman; Margaret James Koziel; Marion G Peters; Raymond T Chung
Journal:  J Interferon Cytokine Res       Date:  2006-11       Impact factor: 2.607

2.  Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicity.

Authors:  A Tamir; W J Jordan; M Ritter; N Habib; R I Lechler; G R Foster; G Lombardi
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

3.  Activation of TGF-β1 promoter by hepatitis C virus-induced AP-1 and Sp1: role of TGF-β1 in hepatic stellate cell activation and invasion.

Authors:  Lance D Presser; Steven McRae; Gulam Waris
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

4.  Abnormalities in Cu and Zn levels in acute hepatitis of different etiologies.

Authors:  K Papanikolopoulos; A Alexopoulou; A Dona; E Hadziyanni; L Vasilieva; S Dourakis
Journal:  Hippokratia       Date:  2014-04       Impact factor: 0.471

5.  Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection.

Authors:  Caralee J Schaefer; Karl Kossen; Sharlene R Lim; Jiing-Huey Lin; Lin Pan; Williamson Bradford; Patrick F Smith; Scott D Seiwert
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

6.  Simultaneous determination of xanthopterin and isoxanthopterin in human urine by synchronous fluorescence spectroscopy.

Authors:  Yi-Qun Wan; Li-Juan Tang; Ting Tan
Journal:  J Fluoresc       Date:  2010-04-24       Impact factor: 2.217

7.  Hepatitis C virus-induced furin and thrombospondin-1 activate TGF-β1: role of TGF-β1 in HCV replication.

Authors:  Lance D Presser; Adam Haskett; Gulam Waris
Journal:  Virology       Date:  2011-02-05       Impact factor: 3.616

8.  Negative regulation of hepatitis C virus specific immunity is highly heterogeneous and modulated by pegylated interferon-alpha/ribavirin therapy.

Authors:  Mark A A Claassen; Robert J de Knegt; Duygu Turgut; Zwier M A Groothuismink; Harry L A Janssen; André Boonstra
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

9.  Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin.

Authors:  Debora Lucia Seguro Danilovic; Maria Cassia Mendes-Correa; Maria Cristina Chammas; Heverton Zambrini; Suemi Marui
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 10.  Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis.

Authors:  Alessia Virzì; Armando Andres Roca Suarez; Thomas F Baumert; Joachim Lupberger
Journal:  Cold Spring Harb Perspect Med       Date:  2020-01-02       Impact factor: 5.159

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.